Document is current
Any future updates will be listed below
-
Authors
Bortolus, Renata https://orcid.org/0000-0003-3857-4133
Filippini, Francesca https://orcid.org/0000-0001-5884-8635
Udali, Silvia
Rinaldi, Marianna
Genesini, Sabrina
Gandini, Giorgio
Montagnana, Martina https://orcid.org/0000-0001-8999-0001
Chiaffarino, Francesca https://orcid.org/0000-0001-6009-8108
Lippi, Giuseppe https://orcid.org/0000-0001-9523-9054
Pattini, Patrizia
De Grandi, Gelinda
Olivieri, Oliviero https://orcid.org/0000-0001-8209-9056
Parazzini, Fabio https://orcid.org/0000-0001-5624-4854
Friso, Simonetta https://orcid.org/0000-0002-9606-6711
-
Funding
Funding for this research was provided by:
Bayer S.p.A. (The funder had no role in study design, data collection, analysis or interpretation; or writing manuscript.)
Università degli Studi di Verona
- License Information
-
More Information
Article History
Received: 26 February 2020
Accepted: 24 November 2020
First Online: 29 December 2020
Change Date: 1 February 2021
Change Type: Update
Change Details: Former problem: Funding information was missing and Correct information: Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement
Compliance with ethical standards
:
: FP was involved in Bayer Italy and Sanofi Italy Board. The other authors report no conflicts of interest.
: The study was approved by the Ethical Committee of the Verona University Hospital. Eligible subjects were informed about the objectives and procedures of the study. All participants provided written informed consent before enrolment. The procedures used were in accordance with the ethical standards of the responsible institutional or regional committee on human experimentation or in accordance with the Helsinki Declaration of 1975 as revised in 1983.
